Sanyou Biopharmaceuticals is a high-tech biopharmaceutical company driven by the mission of “To make it easy to develop new drugs worldwide”. Guided by the vision “To become a front-runner in global innovative drug R&D”, the company focuses on the R&D and commercialization of innovative drugs.

With AI-STAL, the world's leading AI-enabled super-trillion molecular library, as our source of innovation and SAI-DA, our intelligent drug-discovery accelerator integrating dry-lab (in silico) and wet-lab work, as our core engine, we are building an open innovation ecosystem through Clicklinks, our original-drug innovation hub, to collaborate with partners, advance our drug pipeline toward commercialization and benefit patients worldwide.

Headquartered in Shanghai, China, with business centers established across Asia, North America, Europe, and other regions, forming a global business network, Sanyou has more than 20,000 m² of operational and planned R&D and GMP facilities.

Sanyou has established strong partnerships with more than 2,000 pharmaceutical and biotechnology companies worldwide. We have signed 100+ collaborative R&D agreements. More than 10 drug candidates from these collaborations have progressed to preclinical or clinical development. We have also completed 1,000+ drug discovery and stage-specific R&D projects and delivered thousands of branded products.

The company has filed more than 180 invention patent applications, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.

Shanghai, China:

Boston, United States:

San Diego, United States:

Philadelphia, United States:

London, United Kingdom: